Lumakras (sotorasib) — United Healthcare
rectal cancer
Initial criteria
- Diagnosis of rectal cancer
- Tumor is KRAS G12C-mutation positive
- Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lumakras therapy
Approval duration
12 months